These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 29884866)

  • 1. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
    Song W; Shen L; Wang Y; Liu Q; Goodwin TJ; Li J; Dorosheva O; Liu T; Liu R; Huang L
    Nat Commun; 2018 Jun; 9(1):2237. PubMed ID: 29884866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model.
    Golchin S; Alimohammadi R; Rostami Nejad M; Jalali SA
    J Cell Physiol; 2019 Nov; 234(11):19866-19874. PubMed ID: 30941773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
    Guo J; Yu Z; Sun D; Zou Y; Liu Y; Huang L
    Mol Cancer; 2021 Jan; 20(1):10. PubMed ID: 33407548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival.
    Goodwin TJ; Shen L; Hu M; Li J; Feng R; Dorosheva O; Liu R; Huang L
    Biomaterials; 2017 Oct; 141():260-271. PubMed ID: 28700955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.
    He C; Duan X; Guo N; Chan C; Poon C; Weichselbaum RR; Lin W
    Nat Commun; 2016 Aug; 7():12499. PubMed ID: 27530650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tumor microenvironment responsive biodegradable CaCO
    Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
    Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
    Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
    J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
    Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
    Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
    Gou HF; Huang J; Shi HS; Chen XC; Wang YS
    PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
    Zhang M; Jiang H; Zhang R; Jiang H; Xu H; Pan W; Gao X; Sun Z
    J Cell Biochem; 2019 Jun; 120(6):10239-10247. PubMed ID: 30609118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors.
    Duan X; Chan C; Han W; Guo N; Weichselbaum RR; Lin W
    Nat Commun; 2019 Apr; 10(1):1899. PubMed ID: 31015397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
    Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
    J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.
    Miao L; Li J; Liu Q; Feng R; Das M; Lin CM; Goodwin TJ; Dorosheva O; Liu R; Huang L
    ACS Nano; 2017 Sep; 11(9):8690-8706. PubMed ID: 28809532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
    Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
    BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.